香港泌尿外科学会与香港泌尿肿瘤学会关于转移性前列腺癌管理的共识声明
香港两个主要前列腺癌专业组织联合组织12名专家组成共识小组,围绕转移性前列腺癌管理的6个最关键争议领域,采用改良德尔菲法经多次小组会议讨论临床经验与已发表文献,最终投票接受并建立45条共识声明。声明主要基于最新临床证据和主要海外指南,并考虑本地临床经验与可行性,被认为适用于香港医生管理转移性前列腺癌患者。
要点
- 香港泌尿外科学会与香港泌尿肿瘤学会联合制定转移性前列腺癌管理共识。
- 12名专家围绕6个最关键争议领域,采用改良德尔菲法形成45条共识声明。
- 共识声明基于最新临床证据和主要海外指南,并考虑本地临床经验与可行性。
核心结论
- 共接受并建立45条关于转移性前列腺癌管理的共识声明,被认为适用于香港医生管理转移性前列腺癌患者。
研究设计与样本
- 由香港代表前列腺癌专家的两个主要专业组织联合组织本地专家共识,共识小组共纳入12名专家。
- 识别出关于转移性前列腺癌管理6个最关键且相关的争议领域,采用改良德尔菲法多次召开小组会议讨论临床经验与相关已发表文献,最终会议对每条起草声明按本地推荐可行性由每位成员投票。
主要发现
- 小组投票后最终接受并建立45条关于转移性前列腺癌管理的共识声明。
- 共识声明主要来源于最新临床证据和主要海外指南,并考虑本地临床经验与可行性。
临床怎么用
- 这些共识声明被认为是对香港医生管理转移性前列腺癌患者的适用推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To establish a set of consensus statements to facilitate physician management strategies for patients with metastatic prostate cancer (mPCa) in Hong Kong. A local expert consensus was organized jointly by the two main professional organizations representing prostate cancer specialists in Hong Kong. A total of 12 experts were included in the consensus panel. Six of the most crucial and relevant areas of debate regarding the management of mPCa were identified. With the use of a modified Delphi method, several panel meetings were held for the members to discuss their clinical experience and the published literature relevant to the areas of debate. At the final meeting, each drafted statement was voted on by every member based on its practicability of recommendation in the locality. After the panel voting, a total of 45 consensus statements regarding the management of mPCa were ultimately accepted and established. The consensus statements were primarily derived from the latest clinical evidence and major overseas guidelines, with the consideration of local clinical experience and practicability. These are considered applicable recommendations for Hong Kong physicians for the management of mPCa patients.
引用
- Poon DM, Chan CK, Chan TW, et al. Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. BJU Int. 2018. PMID: 29211320. doi:10.1111/bju.14091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。